You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
千金藥業(600479.SH):婦科千金片/膠囊在公立醫療婦科炎症中成藥市場的份額佔比增至2022年的21.8%,排名婦科中成藥第一名
格隆匯 04-20 09:44

格隆匯4月20日丨有投資者在投資者互動平台向千金藥業(600479.SH)提問,“現在全國醫院五萬家,公司千金片進了多少醫院?未來發展空間大不大?目前目前拓展醫院投入資源怎樣?”

千金藥業回覆稱,公司婦科千金片/膠囊在公立醫療婦科炎症中成藥市場的份額佔比從2017年的17.0%增長至2022年的21.8%,排名婦科中成藥第一名。公司針對醫療終端,積極參與學術交流、論文賦能、產品研發及公益活動,促進學術、公益及研發等資源的整合,並通過推廣產品臨牀研究成果,使醫生了解熟悉並認可公司產品特點及療效,從而確保產品在臨牀的合理使用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account